FDA Approves Koselugo for Pediatric Neurofibromatosis Treatment FDA Approves Koselugo for Pediatric Neurofibromatosis Treatment
The approval of selumetinib was based on results from the phase 2 SPRINT Stratum trial investigating the efficacy of the drug on kids who have NF1 with symptomatic, inoperable plexiform neurofibromas.FDA Approvals
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Neurology & Neurosurgery News Source Type: news
More News: Brain | Cancer & Oncology | Children | Hematology | Neurofibromatosis | Neurology | Neurosurgery | Pediatrics